BriaCell Therapeutics Corp. BCTX
3.06 USD -0.10 (-3.32%)
Regular-session close
3.10 +0.04 +1.31%
After hours · Nov 20, 5:59 PM ET
3.02 Day range 3.20
2.74 52-week range 12.64
- YTD
- -56.96%
- 1 year
- -56.41%
News
defenseworld.net Briacell Therap (NASDAQ:BCTX) Shares Break Above 200 Day Moving Average – Should You Sell? Shares of Briacell Therap (NASDAQ: BCTX - Get Free Report) passed above its 200-day moving average during trading on Friday. The stock has a 200-day moving average of $3.79 and traded as high as…
globenewswire.com BriaCell and BriaPro Present Positive Preclinical Immunotherapy Data Across Four Posters at SITC 2026 PHILADELPHIA and VANCOUVER, British Columbia, Nov. 06, 2026 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXL) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage…
globenewswire.com BriaCell Awarded 2026 “Immunotherapy Solution of the Year” By BioTech Breakthrough LOS ANGELES, Nov. 05, 2026 (GLOBE NEWSWIRE) -- BioTech Breakthrough, a leading independent market intelligence organization that evaluates and recognizes standout life sciences and biotechnology…
globenewswire.com BriaCell and BriaPro to Present Preclinical Anti-Cancer Activity and Immunotherapy Findings at SITC 2026 Four presentations highlight BriaCell's Bria-OTS+™ cellular immunotherapy platform and BriaPro's CD80-based immunotherapy programs In vitro Bria-OTS+ studies demonstrate immune-cell activation and…
globenewswire.com BriaCell Announces ESMO 2026 Poster Highlighting Circulating Immune Biomarker Associated with Clinical Outcomes in Metastatic Breast Cancer PHILADELPHIA and VANCOUVER, British Columbia, Oct. 23, 2026 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXL) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage…
globenewswire.com BriaCell and BriaPro to Present Four Posters at SITC 2026 Annual Meeting PHILADELPHIA and VANCOUVER, British Columbia, Oct. 06, 2026 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXL) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage…
globenewswire.com Data Safety Monitoring Board (DSMB) Recommends Continuing BriaCell's Phase 3 Metastatic Breast Cancer Study PHILADELPHIA and VANCOUVER, British Columbia, Sept. 14, 2026 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXL) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage…
globenewswire.com BriaCell's Pivotal Phase 3 Metastatic Breast Cancer Study Expands to Leading Cancer Center PHILADELPHIA and VANCOUVER, British Columbia, Sept. 08, 2026 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXL) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage…
globenewswire.com BriaCell Advances Personalized Melanoma Immunotherapy Vaccine Candidate, Bria-MEL+™ Cell-based immunotherapy program is designed to harness patients' own immune systems Bria-MEL+ is a personalized, off-the-shelf immunotherapy vaccine candidate intended to enable patient specific…
globenewswire.com BriaCell Receives FDA Clearance to Initiate Bria-PROS+™ Clinical Study in Prostate Cancer FDA clearance of Investigational New Drug (IND) application enables BriaCell to initiate Phase 1/2a clinical study of Bria-PROS+ in prostate cancer Bria-PROS+ is BriaCell's next generation…
globenewswire.com BriaCell Opens First Canadian Site – Sunnybrook – for Pivotal Phase 3 Trial in Metastatic Breast Cancer PHILADELPHIA and VANCOUVER, British Columbia, July 16, 2026 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXL) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage…
globenewswire.com BriaCell Arranges Scalable Manufacturing with FUJIFILM Biotechnologies for Bria-IMT™ PHILADELPHIA and VANCOUVER, British Columbia, July 15, 2026 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXL) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage…
globenewswire.com BriaCell Engages Consulting and Branding Firms to Support Commercial and Market Access Evaluation of Bria-IMT™ PHILADELPHIA and VANCOUVER, British Columbia, July 07, 2026 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXL) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage…
globenewswire.com BriaCell Partners with Uneedle for Scalable Microneedle Administration of Bria-IMT™ PHILADELPHIA and VANCOUVER, British Columbia, June 25, 2026 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXL) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage…
globenewswire.com BriaCell Therapeutics Announces Closing of Offering PHILADELPHIA & VANCOUVER, British Columbia, June 02, 2026 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXL, BCTXZ) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage…
globenewswire.com BriaCell Presents Positive Clinical Data at ASCO 2026 Final Bria-IMT™ Phase 2 data show 55% >1 year and 27% >2-year survival in heavily pre-treated metastatic breast cancer (MBC) patients treated with Bria-IMT regimen selected for Phase 3 TWiST…
globenewswire.com BriaCell Therapeutics Announces Pricing of Offering PHILADELPHIA and VANCOUVER, British Columbia, May 31, 2026 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXL, BCTXZ) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage…
globenewswire.com BriaCell Receives Positive Recommendation from Data Safety Monitoring Board (DSMB) for Phase 3 Study in Metastatic Breast Cancer PHILADELPHIA and VANCOUVER, British Columbia, May 26, 2026 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXL) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage…
globenewswire.com BriaCell Presentations Highlight Positive Clinical Data for Bria-IMT™ at ASCO 2026 PHILADELPHIA and VANCOUVER, British Columbia, May 22, 2026 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXL) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage…
globenewswire.com BriaCell Expands Pipeline to Include an Ovarian Cancer Immunotherapy Candidate, Bria-OVA+™ BriaCell expands push in women's health, building on Phase 2 success in advanced metastatic breast cancer Bria-OVA+, BriaCell's next generation personalized immunotherapy candidate for ovarian…
